Offering patients a pain-free and non-invasive alternative for brain tumour treatment that lasts just 30 minutes, Apollo Hospitals Group on Friday launched South Asia’s first ZAP-X Radiosurgery by the Apollo Hospitals Group, providing a transformative approach to treating brain tumours with minimal radiation exposures. The traditional brain surgery lasts 3-4 hours and longer treatment sessions.
“The ZAP-X platform provides an attractive option for individuals undergoing brain tumour treatment with the shorter treatment sessions further contributing to patient comfort and convenience. By providing a pain-free and non-invasive alternative, the platform offers hope and optimism for patients and their families facing the challenges of brain tumor diagnosis and treatment,” said Dr Prathap Chandra Reddy, Founder Chairman, Apollo Hospitals Group at an event held here to launch the technology.
He added: “This innovative technology designed for the treatment of brain tumours allows for non-invasive, pain-free sessions lasting 30 minutes, with minimal exposure to radiation.
“ZAP-X also comes with advanced safety protocols, including instant error detection and reduced radiation leakage, that ensure the patient’s well-being and quality of life post treatment. Furthermore, as an outpatient procedure it allows for greater convenience and accessibility for patients.”
Prof. John R. Adler, Founder and CEO, Zap Surgical and Professor of Neurosurgery, Stanford School of Medicine said, “Stereotactic radiosurgery is among the most important medical advancements of the past century. Eligible patients no longer must experience debilitating surgical resections, or potentially lose cognitive capacity by undergoing whole-brain radiotherapy. Instead, with ZAP-X radiosurgery, patients can now be quickly treated in an outpatient setting and often return to normal activities the same day with no incisions, and no pain.”
ZAP-X allows for a day-care procedure, enabling patients to return home post-treatment, unlike traditional surgeries requiring 4-7 days or more of hospitalisation, and without the necessity of anesthesia.
This innovative method improves patient outcomes by enhancing the ability to avoid critical structures like the brain stem, eyes, and optic nerves, while also drastically minimizing exposure to healthy brain tissue to safeguard a patient’s cognitive function.
Experts say that ZAP-X’s proven clinical capabilities will enable neurologists and neurosurgeons in treating primary and metastatic brain tumours, Arteriovenous Malformations (AVMs), trigeminal neuralgias, movement disorders such as Parkinson’s disease, Epilepsy and other intracranial lesions such as meningiomas, acoustic neuromas and pituitary adenomas, with better accuracy and fewer side effects to patients.
With the rising tide of Non-Communicable Diseases (NCDs), the experts hope that ZAP-X will be a new addition in the country’s fight against the chronic diseases, of whom cancers form a significant portion.